177 related articles for article (PubMed ID: 12824898)
21. Reduced HGF expression in subcutaneous CT26 tumor genetically modified to secrete NK4 and its possible relation with antitumor effects.
Kubota T; Fujiwara H; Amaike H; Takashima K; Inada S; Atsuji K; Yoshimura M; Matsumoto K; Nakamura T; Yamagishi H
Cancer Sci; 2004 Apr; 95(4):321-7. PubMed ID: 15072590
[TBL] [Abstract][Full Text] [Related]
22. Cooperative interaction between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses.
Matsumoto K; Kataoka H; Date K; Nakamura T
J Biol Chem; 1998 Sep; 273(36):22913-20. PubMed ID: 9722511
[TBL] [Abstract][Full Text] [Related]
23. NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells.
Kubota T; Taiyoh H; Matsumura A; Murayama Y; Ichikawa D; Okamoto K; Fujiwara H; Ikoma H; Nakanishi M; Kikuchi S; Sakakura C; Ochiai T; Kokuba Y; Taniguchi H; Sonoyama T; Matsumoto K; Nakamura T; Otsuji E
Clin Exp Metastasis; 2009; 26(5):447-56. PubMed ID: 19234748
[TBL] [Abstract][Full Text] [Related]
24. The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant.
Parr C; Davies G; Nakamura T; Matsumoto K; Mason MD; Jiang WG
Biochem Biophys Res Commun; 2001 Aug; 285(5):1330-7. PubMed ID: 11478803
[TBL] [Abstract][Full Text] [Related]
25. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells.
Qian LW; Mizumoto K; Inadome N; Nagai E; Sato N; Matsumoto K; Nakamura T; Tanaka M
Int J Cancer; 2003 May; 104(5):542-9. PubMed ID: 12594808
[TBL] [Abstract][Full Text] [Related]
26. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice.
Ueda K; Iwahashi M; Matsuura I; Nakamori M; Nakamura M; Ojima T; Naka T; Ishida K; Matsumoto K; Nakamura T; Yamaue H
Eur J Cancer; 2004 Sep; 40(14):2135-42. PubMed ID: 15341989
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4.
Brockmann MA; Papadimitriou A; Brandt M; Fillbrandt R; Westphal M; Lamszus K
Clin Cancer Res; 2003 Oct; 9(12):4578-85. PubMed ID: 14555533
[TBL] [Abstract][Full Text] [Related]
28. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor.
Date K; Matsumoto K; Shimura H; Tanaka M; Nakamura T
FEBS Lett; 1997 Dec; 420(1):1-6. PubMed ID: 9450538
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy.
Heideman DA; Overmeer RM; van Beusechem VW; Lamers WH; Hakvoort TB; Snijders PJ; Craanen ME; Offerhaus GJ; Meijer CJ; Gerritsen WR
Cancer Gene Ther; 2005 Dec; 12(12):954-62. PubMed ID: 15905856
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4.
Hiscox S; Parr C; Nakamura T; Matsumoto K; Mansel RE; Jiang WG
Breast Cancer Res Treat; 2000 Feb; 59(3):245-54. PubMed ID: 10832594
[TBL] [Abstract][Full Text] [Related]
31. Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association.
Sakai K; Nakamura T; Matsumoto K; Nakamura T
J Biol Chem; 2009 Aug; 284(33):22491-22499. PubMed ID: 19553700
[TBL] [Abstract][Full Text] [Related]
32. Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor-specific T lymphocyte activation.
Kubota T; Taiyoh H; Matsumura A; Murayama Y; Ichikawa D; Okamoto K; Fujiwara H; Ikoma H; Nakanishi M; Kikuchi S; Ochiai T; Sakakura C; Kokuba Y; Sonoyama T; Suzuki Y; Matsumoto K; Nakamura T; Otsuji E
Int J Cancer; 2009 Dec; 125(12):2879-86. PubMed ID: 19588506
[TBL] [Abstract][Full Text] [Related]
33. [Growth suppression of subcutaneous tumor by CT26 expressing NK4 in syngeneic mice].
Kubota T; Fujiwara H; Amaike H; Takashima K; Inada S; Atsuji K; Yoshimura M; Matsumoto K; Nakamura T; Yamagishi H
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2258-60. PubMed ID: 12484049
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy.
Deng XB; Xiao L; Wu Y; Jin F; Mossman B; Testa JR; Xiao GH
Int J Cancer; 2015 Jul; 137(2):481-90. PubMed ID: 25501304
[TBL] [Abstract][Full Text] [Related]
35. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.
Abounader R; Laterra J
Neuro Oncol; 2005 Oct; 7(4):436-51. PubMed ID: 16212809
[TBL] [Abstract][Full Text] [Related]
36. Endometrial cancer invasion depends on cancer-derived tumor necrosis factor-alpha and stromal derived hepatocyte growth factor.
Choi DS; Kim HJ; Yoon JH; Yoo SC; Jo H; Lee SY; Min CK; Ryu HS
Int J Cancer; 2009 Jun; 124(11):2528-38. PubMed ID: 19230022
[TBL] [Abstract][Full Text] [Related]
37. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells.
Jiang WG; Hiscox SE; Parr C; Martin TA; Matsumoto K; Nakamura T; Mansel RE
Clin Cancer Res; 1999 Nov; 5(11):3695-703. PubMed ID: 10589789
[TBL] [Abstract][Full Text] [Related]
38. [NK4 growth inhibition of human Raji lymphoma xenografts by competitive interrupting HGF/Met signal pathway].
Gao Z; Zheng X; Shen R; Zhao H; Cen D; Luo J; Hua S; Pei R; Lyu J
Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):551-5. PubMed ID: 25346127
[TBL] [Abstract][Full Text] [Related]
39. NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor.
Du W; Hattori Y; Yamada T; Matsumoto K; Nakamura T; Sagawa M; Otsuki T; Niikura T; Nukiwa T; Ikeda Y
Blood; 2007 Apr; 109(7):3042-9. PubMed ID: 17179234
[TBL] [Abstract][Full Text] [Related]
40. Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4.
Saimura M; Nagai E; Mizumoto K; Maehara N; Minamishima YA; Katano M; Matsumoto K; Nakamura T; Tanaka M
Clin Cancer Res; 2002 Oct; 8(10):3243-9. PubMed ID: 12374695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
